A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
ModernaTX, Inc.
Study ID
NCT07116616
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • mRNA-2808 — DRUG
    intravenous

Study Details

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

Key Dates

Start date
Sep 30, 2025
Status verified
May 2026
Primary completion
Jun 17, 2030
Completion
Jun 17, 2032

Study Design

Enrollment
166 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: mRNA-2808
    Participants will receive mRNA-2808.

Primary Outcome Measure

Number of Participants with Dose-limiting Toxicity [ Time Frame: Up to 28 days ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
University of Alabama at Birmingham HospitalBirminghamAlabama35233-
UCSFSan FranciscoCalifornia94143-
Emory University HospitalAtlantaGeorgia30322-
Mass General BrighamBostonMassachusetts02114-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10065-
Tisch Cancer Institute at Mount SinaiNew YorkNew York10029-
Atrium Health Levine Cancer InstituteCharlotteNorth Carolina28204-
Penn MedicinePhiladelphiaPennsylvania19104-
Sarah Cannon Research InstituteNashvilleTennessee37203-
The Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham Hospital· Birmingham, ALUCSF· San Francisco, CAEmory University Hospital· Atlanta, GAMass General Brigham· Boston, MAMemorial Sloan-Kettering Cancer Center· New York, NYTisch Cancer Institute at Mount Sinai· New York, NY

Related Studies